![]() Sanni Raju, CEO of Natreon states, "it is noteworthy that the triglycerides decreased significantly in the chromium, amla, shilajit complex groups although the dose of fish oil was only 2 g/day and the baseline triglyceride levels were only about 200 mg/dL, because fish oil is known to work better at 4g/day dose, and in hypertriglyceridemia state (triglyceride levels ≥500 mg/dL). Lipid profile, platelet aggregation and glycosylated hemoglobin were evaluated at baseline and at 12 weeks. Endothelial function, as reflection index (RI), biomarkers of oxidative stress – malondialdehyde (MDA), nitric oxide (NO), glutathione (GSH), and inflammatory biomarkers high sensitivity C-reactive protein (hsCRP), inter-cellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), Endothelin-1 (ET-1) were evaluated at baseline, and 4 and 12 weeks. In this randomized, double-blind, parallel group study, 59 type 2 diabetic subjects, who have already been on a stable dose of metformin, in three groups, completed the study: Group A, fish oil 2000 mg Group B, fish oil 2000 mg + trivalent chromium, amla, shilajit complex 10 mg (200 μg of Cr3+) and Group C, fish oil 2000 mg + chromium, amla, shilajit combination 20 mg (400 μg of Cr3+) daily for 12 weeks (2000 mg of fish oil contained 600 mg of EPA and 400 mg of DHA). The study shows evidence that the trivalent chromium, amla and shilajit complex significantly improves the efficacy of fish oil in addressing cardiovascular risk factors. doi:0.1016/B978-0-12-384947-2.NEW BRUNSWICK, N.J., Ap/PRNewswire-PRWeb/ - Natreon announces publication of a randomized, double-blind clinical study on the effect of trivalent chromium, amla and shialjit when combined with fish oil. Chromium picolinate supplementation for overweight or obese adults. Using the adequate intake for nutrient assessment of groups. National Center for Biotechnology Information, U.S. A meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity. Tsang C, Taghizadeh M, Aghabagheri E, Asemi Z, Jafarnejad S. ![]() The influences of chromium supplementation on glycemic control, markers of cardio-metabolic risk, and oxidative stress in infertile polycystic ovary syndrome women candidate for in vitro fertilization: A randomized, double-blind, placebo-controlled trial. Jamilian M, Zadeh Modarres S, Amiri Siavashani M, et al. ![]() Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. The effects of supplementation with chromium on insulin resistance indices in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trials. Heshmati J, Omani-Samani R, Vesali S, et al. Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis. Chromium supplementation reduces resting heart rate in patients with metabolic syndrome and impaired glucose tolerance. Nussbaumerova B, Rosolova H, Krizek M, et al. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. doi:10.2337/diab.Ĭostello RB, Dwyer JT, Bailey RL. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Chromium.Īnderson RA, Cheng N, Bryden NA, et al. ![]() ![]() Chromium: Fact sheet for health professionals. ![]()
0 Comments
Leave a Reply. |